+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Antihypertensives Market: By Drug Class: Global Industry Perspective, Comprehensive Analysis and Forecast, 2018 - 2025

  • ID: 5143151
  • Report
  • November 2019
  • Region: Global
  • 110 pages
  • Zion Market Research
1 of 2
The report covers forecast and analysis for the antihypertensives market on a global and regional level. The study provides historic data from 2016 along with forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints for the antihypertensives market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the antihypertensives market on a global as well as regional level.

According to the report, global demand for antihypertensives market was valued at approximately USD 26.18 billion in 2018, and is expected to generate revenue of around USD 30.62 billion by end of 2025, growing at a CAGR of around 2.3% between 2019 and 2025.

In order to give the users of this report a comprehensive view on the antihypertensives market we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the key players in the antihypertensives market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new drug class launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the antihypertensives market on global and regional basis.

The study provides a crucial view on the antihypertensives by segmenting the market based on drug class, and region. All the segments of antihypertensives market have been analyzed based on present and future trends and the market is estimated from 2018 to 2025.

Drugs used for treating high blood pressure or hypertension are referred as antihypertensives. Antihypertensive drug class is used to prevent complications associated with high blood pressure, like myocardial infarction and stroke. Research evidences suggest decrease in hypertension related risks like ischaemic heart disease, stroke, heart failure, dementia and mortality by many folds using antihypertensive drugs. Large numbers of antihypertensive drug classes are used to reduce blood pressure. These include vasodilators, renin inhibitors, calcium channel blockers, alpha blockers, beta blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), diuretics and others.

The demand for antihypertensives market is driven by increasing prevalence of hypertension among adults of all age groups, rise in prevalence of cardiovascular diseases, sedentary lifestyle and changing eating habits across the globe. Also, increasing geriatric population, increasing disposable income and health awareness are other factors that boost the market growth. Increasing number of generics and growing competition may act as a restraint to the market growth. Emerging markets with increasing geriatric population base and launch of novel therapies are expected to bring new growth opportunities for major market players operating in the global antihypertensives.

Based on drug class, global antihypertensives market is bifurcated into vasodilators, renin inhibitors, calcium channel blockers, alpha blockers, beta blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), diuretics and other drugs. Diuretics drug class segment held largest market share in 2018. Diuretics are used as first line of treatment for controlling high blood pressure and thus accounted for large market share. Beta blocker and calcium channel blockers drug classes will see rapid growth over the forecast period.

North America dominated the global antihypertensives market in 2018. Increasing prevalence of hypertension, increasing risk of related cardiovascular complications such as stroke, heart failure, ischemic heart disease etc., growing awareness and increasing focus of major players to launch novel therapies with higher efficiency and lower side effects are factors driving the market in this region. Europe was second largest regional market. Increasing geriatric population, presence of developed infrastructure, favorable reimbursement policies and increasing awareness and prevalence of hypertension are some of factors that boost market growth in this region. Latin America is expected to witness moderate growth over the forecast period. Asia Pacific region will exhibit highest growth for antihypertensives market in the coming years. Growing adoption of western culture, sedentary lifestyle, changing eating habits, lack of physical activity, increasing geriatric population and rising prevalence of hypertension and related complications are factors promoting antihypertensives market growth in Asia Pacific. Middle East and Africa will see considerable growth in coming years.

Major players included in the report are AstraZeneca Plc, Johnson & Johnson Ltd., Lupin Limited, Boehringer Ingelheim, Merck & Co., Sanofi S.A., Novartis AG, Pfizer Inc., and Daiichi Sankyo Company Limited among others.

The report segment of global antihypertensives market as follows:

Global Antihypertensives Market: By Drug Class
  • Diuretics
  • Angiotensin receptor blockers (ARBs)
  • Angiotensin converting enzyme (ACE) inhibitors
  • Beta blockers
  • Alpha blockers
  • Calcium channel blockers
  • Renin inhibitors
  • Vasodilators
  • Other Drugs
Global Antihypertensives Market: By Region
  • North America
  • U.S.
  • Europe
  • UK
  • France
  • Germany
  • Asia Pacific
  • China
  • Japan
  • India
  • Latin America
  • Brazil
  • Middle East and Africa
Note: Product cover images may vary from those shown
2 of 2
  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Antihypertensives Market, 2016-2025 (USD Million)
    • 2.2. Antihypertensives Market: Snapshot
  • Chapter 3. Antihypertensives Market - Industry Analysis
    • 3.1. Antihypertensives Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Driver 1
      • 3.2.2. Driver 2
    • 3.3. Restraints
      • 3.3.1. Restraint 1
      • 3.3.2. Restraint 2
    • 3.4. Opportunity
      • 3.4.1. Government funding and support
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis By Product
      • 3.6.2. Market attractiveness analysis by Region
  • Chapter 4. Antihypertensives Market- Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Antihypertensives Market: company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Product launches
      • 4.2.3. Agreements, partnerships, collaborations and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Antihypertensives Market -Product Analysis
    • 5.1. Global Antihypertensives Market overview: By Drug Class
      • 5.1.1. Global Antihypertensives Market share, By Product,2018 and 2025
    • 5.2. Diuretics
      • 5.2.1. Global Antihypertensives Market by Diuretics, 2016-2025 (USD Million)
    • 5.3. Angiotensin receptor blockers (ARBs)
      • 5.3.1. Global Antihypertensives Market By Angiotensin receptor blockers (ARBs), 2016-2025 (USD Million)
    • 5.4. Angiotensin converting enzyme (ACE) inhibitors
      • 5.4.1. Global Antihypertensives Market by Angiotensin converting enzyme (ACE) inhibitors, 2016-2025 (USD Million)
    • 5.5. Beta blockers
      • 5.5.1. Global Antihypertensives Market by Beta blockers, 2016-2025 (USD Million)
    • 5.6. Alpha blockers
      • 5.6.1. Global Antihypertensives Market by Alpha blockers, 2016-2025 (USD Million)
    • 5.7. Calcium channel blockers
      • 5.7.1. Global Antihypertensives Market by Calcium channel blockers, 2016-2025 (USD Million)
    • 5.8. Renin inhibitors
      • 5.8.1. Global Antihypertensives Market by Renin inhibitors, 2016-2025 (USD Million)
    • 5.9. Vasodilators
      • 5.9.1. Global Antihypertensives Market by Vasodilators, 2016-2025 (USD Million)
    • 5.10. Other Drugs
      • 5.10.1. Global Antihypertensives Market by Other Drugs, 2016-2025 (USD Million)
  • Chapter 6. Global Antihypertensives Market - Regional Analysis
    • 6.1. Global Antihypertensives Market overview: by Region
      • 6.1.1. Global Antihypertensives Market share, by Region, 2018 and 2025
    • 6.2. North America
      • 6.2.1. North America Antihypertensives Market, 2016-2025 (USD Million)
      • 6.2.2. North America Antihypertensives Market revenue, By Product,2016-2025 (USD Million)
      • 6.2.3. The U.S.
        • 6.2.3.1. The U.S.Antihypertensives Market revenue, By Product,2016-2025 (USD Million)
      • 6.2.4. Rest of North America
        • 6.2.4.1. Rest of North America Antihypertensives Market revenue, By Product,2016-2025 (USD Million)
    • 6.3. Europe
      • 6.3.1. Europe Antihypertensives Market, 2016-2025 (USD Million)
      • 6.3.2. Europe Antihypertensives Market revenue, By Product,2016-2025 (USD Million)
      • 6.3.3. UK
        • 6.3.3.1. U.K.Antihypertensives Market revenue, By Product,2016-2025 (USD Million)
      • 6.3.4. France
        • 6.3.4.1. France Antihypertensives Market revenue, By Product,2016-2025 (USD Million)
      • 6.3.5. Germany
        • 6.3.5.1. Germany Antihypertensives Market revenue, By Product,2016-2025 (USD Million)
      • 6.3.6. Rest of Europe
        • 6.3.6.1. Rest of Europe Antihypertensives Market revenue, By Product,2016-2025 (USD Million)
    • 6.4. Asia Pacific
      • 6.4.1. Asia Pacific Antihypertensives Market, 2016-2025 (USD Million)
      • 6.4.2. Asia Pacific Antihypertensives Market revenue, By Product,2016-2025 (USD Million)
      • 6.4.3. China
        • 6.4.3.1. China Antihypertensives Market revenue, By Product,2016-2025 (USD Million)
      • 6.4.4. Japan
        • 6.4.4.1. Japan Antihypertensives Market revenue, By Product,2016-2025 (USD Million)
      • 6.4.5. India
        • 6.4.5.1. India Antihypertensives Market revenue, By Product,2016-2025 (USD Million)
      • 6.4.6. Rest of Asia Pacific
        • 6.4.6.1. Rest of Asia Pacific Antihypertensives Market revenue, By Product,2016-2025 (USD Million)
    • 6.5. Latin America
      • 6.5.1. Latin America Antihypertensives Market, 2016-2025 (USD Million)
      • 6.5.2. Latin America Antihypertensives Market revenue, By Product,2016-2025 (USD Million)
      • 6.5.3. Brazil
        • 6.5.3.1. Brazil Antihypertensives Market revenue, By Product,2016-2025 (USD Million)
      • 6.5.4. Rest of Latin America
        • 6.5.4.1. Rest of Latin America Antihypertensives Market revenue, By Product,2016-2025 (USD Million)
    • 6.6. The Middle East and Africa
      • 6.6.1. The Middle East and Africa Antihypertensives Market, 2016-2025 (USD Million)
      • 6.6.2. The Middle East and Africa Antihypertensives Market revenue, By Product,2016-2025 (USD Million)
  • Chapter 7. Company Profiles
    • 7.1. AstraZeneca Plc
      • 7.1.1. Overview
      • 7.1.2. Financials
      • 7.1.3. Product Portfolio
      • 7.1.4. Business Strategy
      • 7.1.5. Recent Developments
    • 7.2. Johnson & Johnson Ltd
      • 7.2.1. Overview
      • 7.2.2. Financials
      • 7.2.3. Product Portfolio
      • 7.2.4. Business Strategy
      • 7.2.5. Recent Developments
    • 7.3. Lupin Limited
      • 7.3.1. Overview
      • 7.3.2. Financials
      • 7.3.3. Product Portfolio
      • 7.3.4. Business Strategy
      • 7.3.5. Recent Developments
    • 7.4. Boehringer Ingelheim
      • 7.4.1. Overview
      • 7.4.2. Financials
      • 7.4.3. Product Portfolio
      • 7.4.4. Business Strategy
      • 7.4.5. Recent Developments
    • 7.5. Merck & Co.
      • 7.5.1. Overview
      • 7.5.2. Financials
      • 7.5.3. Product Portfolio
      • 7.5.4. Business Strategy
      • 7.5.5. Recent Development
    • 7.6. Sanofi S.A.
      • 7.6.1. Overview
      • 7.6.2. Financials
      • 7.6.3. Product Portfolio
      • 7.6.4. Business Strategy
      • 7.6.5. Recent Development
    • 7.7. Novartis AG
      • 7.7.1. Overview
      • 7.7.2. Financials
      • 7.7.3. Product Portfolio
      • 7.7.4. Business Strategy
      • 7.7.5. Recent Development
    • 7.8. Pfizer Inc.
      • 7.8.1. Overview
      • 7.8.2. Financials
      • 7.8.3. Product Portfolio
      • 7.8.4. Business Strategy
      • 7.8.5. Recent Development
    • 7.9. Daiichi Sankyo Company Limited
      • 7.9.1. Overview
      • 7.9.2. Financials
      • 7.9.3. Product Portfolio
      • 7.9.4. Business Strategy
      • 7.9.5. Recent Development
Note: Product cover images may vary from those shown
Adroll
adroll